<span item_type="fundamental" item_id="dacd6dedbb10b6822d48ed46fca53fa6" counter_id="ST/US/EKSO" env="prod"></span><span item_type="announcement" item_id="619398274935032961" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 12.8 M, missing the estimate of USD 14.71 M.</p><p>EPS: As of FY2025, the actual value is USD -4.91.</p><p>EBIT: As of FY2025, the actual value is USD -13.02 M.</p><p></p><h4>Revenue Breakdown</h4><p>Ekso Bionics Holdings, Inc. reported device revenue of $9,241 thousand in 2025, a decrease from $13,323 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. Service and support revenue was $2,918 thousand in 2025, compared to $3,121 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. Subscription revenue decreased to $358 thousand in 2025 from $527 thousand in 2024, and parts and other revenue was $282 thousand in 2025, down from $954 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>.</p><h4>Geographic Revenue</h4><p>Revenue from the Americas decreased to $7,502 thousand in 2025 from $10,133 thousand in 2024, with the United States contributing $7,430 thousand in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. EMEA revenue was $3,792 thousand in 2025, down from $5,942 thousand in 2024, while APAC revenue decreased to $1,505 thousand in 2025 from $1,850 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. Sales denominated in foreign currencies represented approximately 42% of total revenue in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>.</p><h4>Gross Profit and Margin</h4><p>Gross profit decreased by 28% to $6,845 thousand in 2025 from $9,511 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. The gross margin remained consistent at 53% for both 2025 and 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>.</p><h4>Operating Expenses</h4><p>Sales and marketing expenses decreased by 2% to $7,154 thousand in 2025 from $7,308 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. Research and development expenses decreased by 22% to $3,031 thousand in 2025 from $3,874 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. General and administrative expenses increased by 14% to $9,986 thousand in 2025 from $8,789 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. Total operating expenses increased by 1% to $20,171 thousand in 2025 compared to $19,971 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>.</p><h4>Operating and Net Loss</h4><p>Loss from operations increased by 27% to - $13,326 thousand in 2025 from - $10,460 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. Net loss increased by 3% to - $11,695 thousand in 2025 from - $11,330 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>.</p><h4>Other Income (Expense), Net</h4><p>Total other income (expense), net, was $1,631 thousand in 2025, a significant change from - $870 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. This included an unrealized gain on foreign exchange of $1,965 thousand in 2025, compared to an unrealized loss of - $965 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>.</p><h4>Impairment Losses</h4><p>Ekso Bionics Holdings, Inc. recorded an impairment loss of $570 thousand on a trade name intangible asset and an impairment loss of $180 thousand on an intellectual property asset in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>.</p><h4>Cash Flow and Liquidity</h4><p>Net cash used in operating activities increased to - $11,801 thousand in 2025 from - $9,846 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. Net cash used in investing activities increased to - $188 thousand in 2025 from - $37 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. Net cash provided by financing activities was $6,629 thousand in 2025, compared to $7,769 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. Cash and restricted cash at year-end was $1,169 thousand in 2025, down from $6,493 thousand in 2024, and working capital decreased to $5.4 million in 2025 from $11.3 million in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>.</p><h4>Outlook / Guidance</h4><p>Ekso Bionics Holdings, Inc. anticipates that most of its 2026 revenue will come from Enterprise Health sales, with Personal Health product sales increasing quarter over quarter <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. The company expects to begin general commercialization of its Nomad product in late 2026, pending clinical and patient feedback <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>. Additionally, the company is developing partnerships for its Personal Health market, with results expected in 2026 and beyond, and many claims anticipated to be submitted to CMS by partners within the next 12 months <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1549084/000143774926005086/ekso20251231_10k.htm"></span>.</p>

EKSO Bionics | 10-K: FY2025 Revenue Misses Estimate at USD 12.8 M